Table 3.
Distribution of patients by disease type and disease activity across the EDSS scale
| EDSS | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1.5 | 2 | 2.5 | 3 | 3.5 | 4 | 4.5 | 5 | 5.5 | 6 | 6.5 | 7 | 7.5 | 8 | 8.5 | 9 | 9.5 | ||
| R‐R disease (288, 68.57%) | CIS (12; 4.16%) | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R‐R (276; 95.84%) | 71 | 52 | 35 | 58 | 22 | 27 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| A‐T (28; 9.72%) | 1 | 8 | 4 | 7 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| A‐NT (15; 5.2%) | 3 | 5 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| NA‐T (202; 70.13%) | 58 | 31 | 26 | 46 | 14 | 20 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| NA‐NT (43, 14.93%) | 20 | 9 | 4 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Progressive disease (132, 31.43%) | PP (30; 22.73%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 3 | 9 | 12 | 13 | 20 | 9 | 8 | 3 | 3 | 4 | 0 |
| SP (102; 77.27%) | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 1 | 0 | 4 | 6 | 5 | 1 | 2 | 2 | 0 | 0 | 1 | |
| A‐NP (8; 6.06%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |
| A‐P (23; 17.42%) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 1 | 4 | 2 | 5 | 4 | 1 | 0 | 0 | 0 | 0 | |
| NA‐P (48; 36.36%) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 9 | 2 | 5 | 9 | 8 | 11 | 2 | 2 | 1 | 0 | 1 | 0 | |
| NA‐NP (53; 40.15%) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 1 | 1 | 3 | 8 | 8 | 4 | 7 | 4 | 2 | 3 | 1 | |
Each column indicates how many patients with that exact EDSS score are in a given disease type or disease activity subgroup.
Abbreviations: A‐NP, active–not progressive (patient showing disease without progression); A‐NT, active–not treated (patients showing disease activity without receiving treatment); A‐P, active–progressive (patient showing disease and progression at the same time); A‐T, active–treated (patients showing disease activity despite receiving treatment); CIS, clinically isolated syndrome; NA‐NP, not active–not progressive (patient not showing disease activity nor progression); NA‐NT, not active–not treated (patient not showing disease activity without receiving treatment); NA‐P, not active–progressive (patient not showing disease activity while showing progression); NA‐T, not active–treated (patient not showing disease activity while receiving treatment); PP, primary progressive disease; R‐R, relapsing–remitting; SP, secondary progressive disease.